MINIREVIEW

Polish Journal of Microbiology 2021, Vol. 70, No 1, 13–23 https://doi.org/10.33073/pjm-2021-005

# Epidemiology and Pathogenesis of *Staphylococcus* Bloodstream Infections in Humans: a Review

KLAUDIA LISOWSKA-ŁYSIAK<sup>1</sup><sup>(</sup>), RYSZARD LAUTERBACH<sup>2</sup><sup>(</sup>), JACEK MIĘDZOBRODZKI<sup>1</sup><sup>(</sup>) and MAJA KOSECKA-STROJEK<sup>1</sup>\*<sup>(</sup>)

<sup>1</sup>Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland <sup>2</sup>Department of Neonatology, Collegium Medicum, Jagiellonian University, Kraków, Poland

Submitted 22 October 2020, revised 18 December 2021, accepted 12 January 2021

#### Abstract

Staphylococci are among the most frequent human microbiota components associated with the high level of bloodstream infection (BSI) episodes. In predisposed patients, there is a high risk of transformation of BSI episodes to sepsis. Both bacterial and host factors are crucial for the outcomes of BSI and sepsis. The highest rates of BSI episodes were reported in Africa, where these infections were up to twice as high as the European rates. However, there remains a great need to analyze African data for comprehensive quantification of staphylococcal BSI prevalence. The lowest rates of BSI exist in Australia. Asian, European, and North American data showed similar frequency values. Worldwide analysis indicated that both *Staphylococcus aureus* and coagulase-negative staphylococci (CoNS) are the most frequent BSI agents. In the second group, the most prevalent species was *Staphylococcus epidermidis*, although CoNS were not identified at the species level in many studies. The lack of a significant worldwide decrease in BSI episodes indicates a great need to implement standardized diagnostic methods and research etiological factors using advanced genetic methods.

K e y w o r d s: bacteremia, carriage, infection, sepsis, Staphylococcus

# Introduction

Staphylococcus aureus is one of the most frequently isolated pathogens from the hospital or communityacquired infections. Staphylococci are a large group of bacteria in every environment; however, these bacteria can proliferate only in humans or animals. Many staphylococcal species colonize the skin and mucosal membranes, especially the perineum and pharynx. The other sites that harbor these bacteria are the gastrointestinal tract, vagina, and axilla, but carriage in those areas is less frequent (Kosecka-Strojek et al. 2018). Traditionally, staphylococci have been divided into two groups based on the production of extracellular enzyme coagulase: coagulase-positive staphylococci (CoPS) and coagulase-negative staphylococci (CoNS). The first group is represented by well-known opportunistic pathogens such as Staphylococcus aureus, Staphylococcus schleiferi, Staphylococcus intermedius, and Staphylococcus pseudintermedius, and the second group traditionally includes nonpathogenic or opportunistic pathogens; however, recently, several clinical reports have presented CoNS as dangerous pathogens, particularly for newborns or immunocompromised patients (Heilmann et al. 2019). A few species, namely *Staphylococcus hyicus*, *Staphylococcus agnetis*, and *Staphylococcus felis*, belong to the third group – coagulase-variable staphylococci. These species are usually grouped with CoPS but cannot produce clumping factors, and coagulase production tests give variable results (Becker et al. 2014). As opportunistic pathogens, staphylococci exhibit saprophytic characteristics under physiological conditions, but the bacteria become severe pathogens under additional infection-facilitating conditions.

Staphylococci are etiological agents of diseases with various localizations, manifestations and/or courses of infection. The most frequent infections are local infections, and the bacteria can cause lesions in various anatomical tissues. Overall, the infections are grouped into skin and soft tissue infections (SSTIs) with

Corresponding author: M. Kosecka-Strojek, Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland, e-mail: maja.kosecka-strojek@uj.edu.pl
2021 Klaudia Lisowska-Łysiak et al.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (https://creativecommons.org/licenses/by-nc-nd/4.0/).

manifestations such as dermatitis, abscesses, furunculosis, boils, folliculitis, impetigo, or mastitis, and also includes other severe diseases such as staphylococcal foodborne disease, toxic shock syndrome, and staphylococcal scalded skin syndrome (SSSS) (Foster 2012; Tong et al. 2015). Staphylococci are also common pathogens of deep tissue infections, including foreign bodies infection. Most studies focused on *S. aureus* infections, but there is strong evidence of the CoNS involvement in severe diseases. Osteomyelitis, otitis, wound infection, endophthalmitis, urinary tract infection, meningitis, or even pneumonia may be caused by *S. epidermidis, Staphylococcus saprophyticus, Staphylococcus lugdunensis*, and *S. schleiferi* (von Eiff et al. 2002; Becker et al. 2014; Argemi et al. 2019). When staphylococci gain

temic as bacteremia and then advances to infection. The literature was screened based on a PubMed search using the terms "staphylococci", *"Staphylococcus*" and "bloodstream infections" and/or "sepsis". The publications were then evaluated based on a citation index. Specific criteria were used to describe the worldwide occurrence of *S. aureus*, and CoNS bloodstream infections and/or sepsis, such as: only original articles were included; the data from different geographical regions/countries were analyzed; the articles with the highest number of participants and bacterial strains isolated, and those containing long-term studies or the recent data, were selected to the analysis.

entry into the bloodstream, colonization becomes sys-

## Bacteremia, bloodstream infection, and sepsis

**Bacteremia.** Bacteremia is characterized by the presence of pathogens in the blood (Pai et al. 2015). Transient bacteremia is limited to one or two days, without any manifestations, and may be caused by some staphylococcal species. Furthermore, the phenomenon does not indicate any further manifestation in healthy hosts (Samet et al. 2006). The presence of bacteria in the blood is eliminated by immunological defense systems and is known in the literature as "natural bacteremia".

**Bloodstream infection.** However, in predisposed hosts, bacteremia advances to bloodstream infection (BSI), manifesting as an inflammatory response against microorganisms or/and against their metabolites present in the body (Dayan et al. 2016). The BSI can be successfully treated or advances to sepsis (Thomer et al. 2016; Michalik et al. 2020). Sepsis is related to organ dysfunction, perfusion disturbances, or hypotension with accompanying lacticaemia, oliguria, and/or psychological disorders (Samet et al. 2006; Hotchkiss et al. 2016).

Therefore, some *S. aureus* bacteremia complications, such as endocarditis, attributable mortality, embolic

stroke, or recurrent infection during the 12-week follow-up period, are circumstances associated with the increased sepsis frequency from 11% to 43%. When the inflammatory response is triggered by the massive release of pro-inflammatory Th1 cytokines, such as TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IFN- $\gamma$ , a septic shock may occur (Dayan et al. 2016).

Sepsis. Sepsis is the incorrect, inflammatory response of the host organism to infection, and often, it is a result of systemic bloodstream infections. Recently, sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al. 2016). Untreated sepsis can lead to severe sepsis or septic shock and, consequently, multiple organ failure (Sequential Organ Failure Assessment, SOFA) and death (Stevenson et al. 2016). Sepsis is a critical clinical stage of general toxemia and organ dysfunction, and a patient's inflammatory response interferes with the functioning of vital organs, such as the heart, kidneys, lungs, or liver. Sepsis-3 recommends a new sepsis scoring system, rapid sequential assessment of organ failure (qSOFA), consisting of 3 elements: an altered mental state, respiratory rate, and systolic blood pressure (Minejima et al. 2019). Patients with suspected infection expected to have a prolonged ICU stay can be identified at the bedside with quick SOFA, i.e., alteration in mental status, systolic blood pressure  $\leq 100 \text{ mmHg}$ , or respiratory rate  $\geq$  22/min. Moreover, patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP  $\geq$  65 mmHg and having a serum lactate level >2 mmol/l (18 mg/dl) despite adequate volume resuscitation (Singer et al. 2016).

# Pathogenicity of staphylococcal bloodstream infections

Antibiotic resistance. Staphylococci exhibit a wide resistance to antibiotics. One of the most dangerous features of staphylococci is their multi-resistance. Research indicates that both the CoPS and CoNS species have staphylococcal chromosome cassettes mec (SCCmec) that determine resistance to methicillin in both groups. Furthermore, the SCCmec elements of CoNS present extreme diversity, which causes many diagnostic problems (Hosseinkhani et al. 2018). The increase of methicillin-resistant S. aureus (MRSA) isolates in hospital and the community due to horizontal gene transfer across bacterial species occurred. The environmental and animal-associated CoNS may be underestimated factor for the spread of the resistance genes into more pathogenic species like S. aureus (Kosecka-Strojek et al. 2016; Lisowska-Łysiak et al. 2019). Methicillin and vancomycin resistance remain the major antimicrobial resistance phenotype of concern. Although still relatively infrequent, multi-resistant CoNS with reduced susceptibility to glycopeptides are emerging pathogens of clinical concern and should be kept in mind in empirical and rational therapy of BSI (Veach et al. 1990; Natoli et al. 2009). In recent years an emerging spread of linezolid-resistant *Staphylococcus capitis* and *S. epidermidis* strains in Europe was shown (Tevell et al. 2017; Kosecka-Strojek et al. 2020). An increased resistance is the result of antibiotic pressure, which could select resistant clones among staphylococci.

Virulence determinants and other invasion/evasion determinants. Staphylococci exhibit a strong capacity to infect human hosts by using specific strategies to enable the adherence, invasion, persistence, and evasion of the host's immunity mechanisms. However, the infection ability is not similar for all species within the Staphylococcus genus. In general, CoNS isolates present lower levels of virulence determinants than CoPS, but the factors involved in colonization support invasion in the host (Becker et al. 2014). It is especially true in extremely immature infants, in whom more than 80% of late-onset sepsis (diagnosed after 72 hours of life) is caused by CoNS (Lauterbach et al. 2016; Wójkowska-Mach et al. 2019). However, despite the relatively low level of virulence, immature infants with sepsis caused by these pathogens present a wide range of clinical symptoms (Lauterbach et al. 2016). It was shown that S. lugdunensis was responsible for sepsis and endocarditis on the 1st day of life in a term newborn, which underwent lotus birth (Ittleman and Szabo 2018). In contrast, S. aureus strains often exhibit a vast arsenal of toxins and enzymes involved in staphylococcal pathogenesis. Toxins can lead to a weak response of the human organism because they can degrade certain host cells, manipulate the innate and adaptive immune response, and degrade intercellular junctions, contributing to the S. aureus proliferation (Oliveira et al. 2018).

**Toxins.** One of *S. aureus* toxicity mechanisms is damage to host cell membranes caused by hemolysins, bicomponent leukocidins, or phenol-soluble modulins (Herrera et al. 2016). However, it has been proven that CoNS also secrete toxins and enzymes. Based on CoNS strains whole-genome sequencing (WGS) performed by Argemi et al. (2019), the presence of proteases, lipases, and hemolysins genes in *S. epidermidis*, *S. capitis*, and *Staphylococcus caprae* was shown. Moreover, enterotoxin genes in *S. epidermidis* and *Staphylococcus haemolyticus* genomes were shown (Nanoukon et al. 2018; Argemi et al. 2019). Other toxins produced by *S. aureus* are usually infection-specific, such as enterotoxins or toxic shock syndrome toxin. Furthermore, bacteria-host interactions depend on extracellular

enzymes, and the largest group of enzymes includes proteases. This category consists of serine proteases, the metalloprotease aureolysin, and staphopains that are engaged in the evasion of complement-mediated killing, host tissue destruction, immunoglobulin degradation, and deregulation of fibrinolysis (Miedzobrodzki et al. 2002; Sabat et al. 2008; Kalińska et al. 2012; Martínez-Garcia et al. 2018).

Biofilm formation. Biofilm formation is an additional factor associated with CoPS and CoNS infections (Grzebyk et al. 2013; Argemi et al. 2019). Biofilm formation is one of the staphylococcal survival strategies within host organisms. The presence of staphylococcal biofilms is a key factor involved in bacterial resistance to various groups of antibiotics. Bacterial biofilms are defined as communities of bacterial colonies attached to the host surface and surrounded by exopolymeric matrix substances strictly regulated by numerous proteins engaged in the biofilm life cycle. It was shown that biofilms could evade the host immune response, which leads to the persistence of staphylococci. Bhattacharya et al. (2018) proved that S. aureus biofilms could release leukocidins, which affect extracellular trap formation and allow evasion of neutrophil-mediated killing. Biofilm production has also been proven for CoNS species, including S. lugdunensis that produces adhesins and other biofilm promoters (Argemi et al. 2017). Staphylococcal pathogenesis is a process that involves an array of extracellular proteins, biofilm, and cell wall components that are coordinately expressed in different phases of infection. The expression or suppression of two divergent loci, accessory gene regulator (agr) and staphylococcal accessory regulator (sar) are recognized as critical regulators of virulence in staphylococci (Arya and Princy 2013).

Risk factors present in humans: predisposed patients. Several studies have shown that host risk factors may significantly enhance the effects of BSIs, including mortality. The high-risk group of staphylococcal infections contains mostly patients with indwelling medical devices. The highly predisposed groups also contain premature newborns or elderly patients or multimorbid, chronically ill, or immunosuppressed patients. A large group of the patients infected is also those with inserted foreign plastic bodies, such as implants and venflons.

The essential patients' factors that determine bloodstream infections and complications are age, presence of comorbidities, and appropriate initial antibiotic treatment (Ayau et al. 2017). Bloodstream infections occur in elderly patients over 75 years old, resulting in increased mortality (Gasch et al. 2013). A 9-year study performed by Ayau et al. (2017) underlined risk factors that increased the probability of mortality, such as age, cancer, heart disease, neurological disease, nursing home residence, and Charlson score greater than 3. In fact, cancer itself increases the 30-day mortality, but Bello-Chavolla et al. (2018) reported additional risk factors, including hematologic malignancy, hyperglycemia, abdominal source of infection, and endocarditis, based on studies conducted on patients with cancer. Malignancy was also confirmed to be a key factor associated with poor outcomes of infection in other studies (Papadimitriou-Olivgeris et al. 2019).

# Epidemiology: Worldwide distribution of staphylococcal bloodstream infections

Staphylococcal bloodstream infections are currently a challenging issue for clinicians, diagnosticians, and microbiologists, primarily due to their high frequency worldwide. Studies on bloodstream infection episodes differ slightly from each other because of the high number of patients and the number of institutions involved in providing the data. Interestingly, all of these studies confirmed a high number of staphylococci isolated from blood samples, ranging from 23.9 to 79.2% (Table I). In many cases, S. aureus, usually MRSA isolates, and CoNS were the predominant species involved in BSI episodes. However, most importantly, staphylococcal bloodstream infections affect the whole world, not only developing countries. It is imperative to analyze the data to implement standard diagnostic methods, to compare the results among various countries, to evaluate existing preventive measures, and to plan effective infection prevention and control programs or establish new programs, including the use of advanced genetic methods (Dik et al. 2016; Sabat et al. 2017; Kosecka-Strojek et al. 2019). This study compares staphylococcal bloodstream infections in the world. The evaluation of S. aureus and CoNS as etiological agents of BSI of the cited publications was made under the following criteria: the studies included patients with symptoms of BSI/sepsis; pathogens grew on at least one percutaneous blood culture and a culture of the catheter tip; bacteria have been identified as S. aureus or CoNS species using commercial/automated identification tests; susceptibility testing was performed, and CoNS species from positive blood samples were included in comprehensive data for analysis except where specified in the laboratory records as contaminants.

**Europe.** The epidemiology of BSI episodes in Europe was analyzed in detail. The European Centre for Disease Prevention and Control (ECDC 2008; 2018) presented that CoNS were the most numerous bloodstream infections pathogens isolated in Europe. Moreover, the biggest groups of infected patients consisted of neonates and children, and the probability of serious complications such as long-term adverse neurological outcomes or mortality remained high for these infections (Zingg et al. 2017). Deptuła et al. (2018) reported that catheterrelated BSI episodes in Poland occurred in 48.9% of the patients analyzed, and the predominant pathogens were CoNS. These results suggest a strong need for the construction of functional incidence-based surveillance programs in Poland to reduce BSI episodes. The Neonatology Surveillance Network (PNSN) prepared one of these programs and focused on late-onset BSI (LO-BSI) in very-low-birth-weight infants. The study showed that CoNS were the most common cause of LO-BSI (Wójkowska-Mach et al. 2014). Both studies confirmed that it is necessary to implement a national program for infectious disease monitoring and prevention.

Another study in Germany focused on pediatric BSI was based on 20 years of sample collection at a tertiary care hospital. This study conducted a complex observation of a large group of BSI episodes. The results showed an increasing number of CoNS to be responsible for these infections (Hufnagel et al. 2008). Similar results were published by Buetti et al. (2017), which were based on a 7-year surveillance study in Switzerland, although the major pathogen isolated was *Escherichia coli*. These findings were confirmed by other studies performed in Switzerland when staphylococci caused a big group of BSI episodes, but the major isolated pathogens were Gram-negative rods (Papadimitriou-Olivgeris et al. 2019).

On the other hand, an increase in the presence of CoNS was observed, but a minority of studies identified bacteria to the species level. One of these studies was performed in Sweden and showed the CoNS were related to newborns' sepsis from 1987 to 2014. The authors presented that S. epidermidis (67.4%) was the most frequent pathogen, followed by S. haemolyticus (10.5%), and S. capitis (9.6%) (Ehlersson et al. 2017). The epidemiological study in France was partially consistent with previously mentioned research and showed that E. coli was the primary pathogen in 36% of BSI episodes, followed by S. aureus (16%), and CoNS (8%). The other investigation from France showed the median rate of CoNS in sepsis (12.2%), and all of these strains belonged to S. capitis species (Butin et al. 2017). However, studies in the United Kingdom, Greece, Netherlands, and Romania confirmed that CoNS were predominant pathogens in BSI episodes and sepsis (Cailes et al. 2018; Zlatian et al. 2018; Gkentzi et al. 2019; Zonnenberg et al. 2019).

Asia. A study designed in Japan by Takeshita et al. (2017) showed that the major pathogens isolated from BSIs were CoNS (736 cases, 23%), but *S. aureus* isolates were also among the most commonly isolated strains. These results were comparable to those observed in Europe (Takeshita et al. 2017). The authors also focused on 30-day mortality associated with the species and the

| Table I | Worldwide distribution of staphylococcal bloodstream infections. The gray areas consist of the primary pathogen isolated in studies provided according to adequate reference. |
|---------|---|
|---------|---|

|  | No. | Continent     | Country        | No. of<br>institutions | Years of isolation | Total number<br>of BSI episodes | Staphylo-<br>coccus | Staphylo-<br>coccus (%) | S. aureus | S. aureus<br>(%) | CoNS  | CoNS<br>(%) | Reference                           |
|--|-----|---------------|----------------|------------------------|--------------------|---------------------------------|---------------------|-------------------------|-----------|------------------|-------|-------------|-------------------------------------|
| Africa:     Egypt.     1     2013-2015     65     40.1     6     9.3     20     30.8       Africa:     Ethopia     1     2016-2017     88     84     0.0     7     6     0.3       Africa:     Ethopia     1     2016-2017     88     84     9.0     76     20     20       Asia     Ipam     5     2012-2013     3.34     10.90     3.22     24     9.2     75       Asia     Noth Koras     55     2012-2013     735     549     9.6     69     9.2     756     346       Asia     Noth Koras     55     2012-2014     133     549     9.6     69     76     60     75     60       Asia     Noth Koras     55     2012-2014     183     57     247     42     22     23     345       Asia     Noth Koras     1     2012-2014     183     37     22     245     23       Asia     Noth Koras     1  | 1   | Africa        | Ghana          | 1                      | 2010-2013          | 1,763                           | 507                 | 28.8                    | 76        | 4.3              | 431   | 24.4        | Labi et al. 2016                    |
| Africa:     Ethopia     1     2016-2017     88     38     430     16     180     22     250       Africa:     Pamina     1     2013-2014     103     123     120     6     6     7     60       Asia     Bamina     Sumbiace     5     2012-2013     333     133     120     64     123     268     73     640       Asia     Sumbiaces     5     2012-2015     733     349     865     17     2.2     273     345       Asia     Chinace     1     2015-2016     133     64     892     117     193     568     75     56     57     55     55     55     55     55     55     565     51     565     545 </td <td>2</td> <td>Africa</td> <td>Egypt</td> <td>1</td> <td>2013-2015</td> <td>65</td> <td>26</td> <td>40,1</td> <td>9</td> <td>9.3</td> <td>20</td> <td>30.8</td> <td>Seliem and Sultan 2018</td>  | 2   | Africa        | Egypt          | 1                      | 2013-2015          | 65                              | 26                  | 40,1                    | 9         | 9.3              | 20    | 30.8        | Seliem and Sultan 2018              |
| Africa     Zambia     1     Z013-Z014     103     13     120     6     6     7     6       Asia     Japun     5     202-2013     3.344     1.030     3.22     294     9.2     736     237       Asia     Asia     Varb Sutes     5     2012-2016     73     3.45     17     3.45     17     2.0     2.94     9.2     736     233     3.45       Asia     Chub Sutes     1     2015-2016     133     641     603     8     7.5     56     3.45       Asia     Indian     1     2015-2016     133     641     633     8     7.5     56     3.45       Asia     Indian     1     2012-2016     203     2013     2014     201     203 <td>Э</td> <td>Africa</td> <td>Ethiopia</td> <td>1</td> <td>2016-2017</td> <td>88</td> <td>38</td> <td>43.0</td> <td>16</td> <td>18.0</td> <td>22</td> <td>25.0</td> <td>Sorsa et al. 2019</td>  | Э   | Africa        | Ethiopia       | 1                      | 2016-2017          | 88                              | 38                  | 43.0                    | 16        | 18.0             | 22    | 25.0        | Sorsa et al. 2019                   |
| Asia     Japan     5     2012-2013     3.284     10.30     3.22     294     9.2     736     2374       Asia     South Korea     55     2013-2014     717     349     487     81     11.3     206     345       Asia     Charab States     5     2013-2014     135     56     393     87     72     23     23     345       Asia     Thab States     1     2015-2014     183     64     19.6     39     345       Asia     Tinvant     1     2012-2014     183     87     47.4     42     22.9     45     245       Asia     Asia     1     2008-2015     244     142     144     146     146     146     146     146     143   | 4   |               | Zambia         | 1                      | 2013-2014          | 103                             | 13                  | 12.0                    | 9         | 6.0              | 7     | 6.0         | Kabwe et al. 2016                   |
| Asia     South Korea     55     2013-2014     717     349     487     11.3     268     37.45       Asia     Arab States     4     2013-2015     785     289     36.85     17     2.2     273     3465       Asia     Parb States     4     1     2015-2015     785     58     77     2.7     546     52.8       Asia     Indivat     1     2012-2014     183     87     47.4     420     429     52.6     52.8     54.8 <t< td=""><td>5</td><td></td><td>Japan</td><td>5</td><td>2012-2013</td><td>3,284</td><td>1,030</td><td>32.2</td><td>294</td><td>9.2</td><td>736</td><td>23.0</td><td></td></t<>   | 5   |               | Japan          | 5                      | 2012-2013          | 3,284                           | 1,030               | 32.2                    | 294       | 9.2              | 736   | 23.0        |                                     |
| Aia     Arab States     4     D13-D15     755     265     36.85     17     2.2     2.75     36.65       Aia     Inna     1     D13-D16     133     64     60.3     8     7.5     56     528       Asia     Inna     1     D12-D16     133     64     60.3     8     7.5     55 <t< td=""><td>9</td><td></td><td>South Korea</td><td>55</td><td>2013-2014</td><td>717</td><td>349</td><td>48.7</td><td>81</td><td>11.3</td><td>268</td><td>37.4</td><td>Lee et al. 2015</td></t<>  | 9   |               | South Korea    | 55                     | 2013-2014          | 717                             | 349                 | 48.7                    | 81        | 11.3             | 268   | 37.4        | Lee et al. 2015                     |
| Asia     China     1     2015-2016     133     64     60.3     8     7.5     56     5.3       Asia     Nepal     1     2017-2014     133     64     60.3     8     7.5     56     53       Asia     Taiwarn     India     1     2012-2014     183     87     474     42     273     435     234       Asia     Australia     1     2008-2015     2043     115     403     46     16     173     245       Australia     1     1     2008-2016     203     203     316     453     33.1     453     36.3     453     53.2     54.3     53.3     53.5   |     | Asia          | Arab States    | 4                      | 2013-2015          | 785                             | 289                 | 36.85                   | 17        | 2.2              | 272   | 34.65       |                                     |
| Atia     Nepal     1     2017     56     50     89.2     11     19.6     39     69.6       Asia     India     1     2012-2014     183     87     47.4     42     2.2     4.3     2.45       Asia     India     1     2002-2014     183     87     47.4     42     2.7     4.35     2.45       Astralia     1     1.2     2005-2016     2.03     9.418     7.14     40     7.71     4.93     5.3       Australia     1.1     2005-2016     2.03     5.42     5.41     5.46     5.6     4.6     5.0     4.7       Australia     1     2005-2016     2.05     5.16     7.33     4.6     5.7     5.3   | ~   |               | China          | 1                      | 2015-2016          | 133                             | 64                  | 60.3                    | 8         | 7.5              | 56    | 52.8        | Jiang et al. 2016                   |
| Asia     India     I     2012-2014     I83     87     47.4     4.2     2.29     45     2.45       Asia     Taiwarn     I     2008-2013     2,090     485     23.2     57     243     205       Australia     Australia     1     2008-2013     2,090     485     5,31     6,45     2,7     428     20       Australia     Australia     1     2008-2016     203     1,15     403     46     16.1     69     24.2       Australia     Australia     1     2005-2016     2014     1,833     554     543     646     616     650     79     456     53     13.0       Australia     1     2012-2015     1,823     532     530     150     235     532     532     533     63     536       Europe     Funder     1     2012-2015     1,833     539     50     235     537     64     53     161     67     53     14     153  | 6   |               | Nepal          | 1                      | 2017               | 56                              | 50                  | 89,2                    | 11        | 19.6             | 39    | 69,69       | Thapa et al. 2019                   |
| Asia     Taiwarn     I     2008–2013     2,090     485     2.32     57     2.7     428     20.5       Australia     Australia     Australia     1     2008–2012     9,418     31,60     465     16.1     69     24.3       Australia     Australia     1     2005–2016     203     1145     403     46     16.1     69     24.3       Australia     Australia     1     2005–2016     203     1145     403     46     53     36.3     36.3       Australia     Australia     1     2005–2016     925     542     58.6     46     5.0     496     53.5       Australia     1     2012–2015     1.823     533     300     170     235     13.0       Europe     Switzerland     1     1     2012–2015     1.823     53.0     496     51.1     24.3       Europe     Switzerland     1     1     1882-1955     170     18.9     10.5     14.9     10.5  | 10  |               | India          | 1                      | 2012-2014          | 183                             | 87                  | 47.4                    | 42        | 22.9             | 45    | 24.5        | Bandyopadhyay et al. 2018           |
| AustraliaAustralia $1.33$ $2008-2012$ $9.418$ $3.160$ $5.4.4$ $1.429$ $18.0$ $1.731$ $18.4$ AustraliaAustralia $1.1$ $2005-2016$ $203$ $115$ $40.3$ $46$ $16.1$ $69$ $24.2$ AustraliaAustralia $1.1$ $2005-2016$ $203$ $116$ $79$ $54.1$ $26$ $178$ $53$ $36.3$ AustraliaAustralia $1.1$ $2005-2016$ $925$ $54.1$ $26$ $17.8$ $53$ $36.3$ AustraliaAustralia $1.1$ $2003-2009; 2010-2016$ $925$ $54.1$ $26$ $17.8$ $53$ $30.0$ EuropeSwitzerland $1.1$ $2003-2009; 2010-2016$ $18.0$ $170$ $300$ $170$ $235$ $31.0$ EuropeSwitzerland $1.1$ $2003-2009; 2010-2016$ $1.823$ $53.5$ $30.0$ $300$ $170$ $235$ $13.0$ EuropeSwitzerland $1.1$ $2012-2015$ $32995; 1997-2006$ $1.646$ $650$ $79.2$ $241$ $409$ $75.3$ $140$ EuropeRomania $1.1$ $2006-2017$ $1.83$ $8.4$ $90.4$ $75.3$ $14.0$ $75.3$ $14.0$ $75.3$ EuropeRomania $1.1$ $2006-2017$ $1.70$ $239$ $14.2$ $70$ $75.3$ $14.2$ $75.3$ $14.2$ EuropeRomania $1.2$ $2008-2014$ $9.3$ $3.901$ $20.4$ $70$ $70.2$ $23.3$ $43.1$ <  | 11  | Asia          | Taiwan         | 1                      | 2008-2013          | 2,090                           | 485                 | 23.2                    | 57        | 2.7              | 428   | 20.5        | Chen et al. 2016                    |
| AustraliaAustraliaI $2005-2016$ $203$ $115$ $40.3$ $46$ $16.1$ $69$ $24.2$ AustraliaAustralia $1$ $2005-2016$ $146$ $79$ $54.1$ $26$ $17.8$ $53$ $36.5$ BuropeTurkey $1$ $2003-2009$ , $2010-2016$ $925$ $542$ $58.6$ $46$ $5.0$ $496$ $53.6$ BuropeSwitzerland $1$ $2003-2009$ , $2010-2016$ $925$ $535$ $300$ $17.0$ $235$ $13.0$ BuropeSwitzerland $1$ $2014-2017$ $404$ $78$ $19,3$ $68$ $16.8$ $10$ $29.5$ BuropeSwitzerland $1$ $2014-2017$ $404$ $78$ $19,3$ $68$ $16.8$ $109$ $2.5$ BuropeSwitzerland $1$ $2012-2015$ $32997-2006$ $1,646$ $650$ $79.2$ $241$ $28.1$ $28.1$ $28.1$ $28.1$ $28.1$ $109$ BuropeRomania $1$ $2012-2017$ $170$ $81$ $47.65$ $63$ $37.06$ $18$ $105.9$ BuropeHolland $1$ $2012-2017$ $170$ $81$ $47.65$ $63$ $37.06$ $18$ $105.9$ BuropeVende $1$ $2012-2012$ $2012-2012$ $201$ $201$ $202$ $204$ $201$ $201$ BuropeVende $1$ $1$ $202-2014$ $303$ $24.66$ $650$ $233$ $8.0$ $2.233$ $43.1$ BuropeVende   | 12  | Australia     | Australia      | 23                     | 2008-2012          | 9,418                           | 3,160               | 36.4                    | 1,429     | 18.0             | 1,731 | 18.4        | Si et al. 2016                      |
| Australia     Australia     I     2005-2016     146     79     54.1     26     17.8     53     36.3       Europe     Turkey     1     2003-2009, 2010-2016     925     54.2     58.6     46     5.0     496     53.6       Europe     Switzerland     1     2013-2009, 2010-2015     925     535     30.0     300     17.0     235     13.0       Europe     Switzerland     1     2014-2017     404     78     19.3     68     16.1     97     29.5       Europe     Poland     nd     2012-2015     32.9     150     45.6     53     16.1     97     29.5       Europe     Poland     1     2012-2015     32.9     150     45.6     53     16.1     97     29.5       Europe     Remains     1     2012-2015     170     81     47.65     63     37.06     18     15.1       Europe     Fance     1     2012-2012     2011     28     43.1   | 13  |               | Australia      | 1                      | 2005-2016          | 203                             | 115                 | 40.3                    | 46        | 16.1             | 69    | 24.2        | Worth et al. 2018                   |
| EuropeInrkey1 $2003-2009$ , $2010-2016$ $925$ $542$ $58.6$ $46$ $5.0$ $496$ $53.6$ EuropeSwitzerland20 $2008-2014$ $1,823$ $535$ $300$ $170$ $235$ $13.0$ EuropeSwitzerland1 $2014-2017$ $404$ $78$ $930$ $68$ $16.8$ $10$ $2.5$ EuropeSwitzerlandnd $2012-2015$ $3297$ $150$ $792$ $2912$ $2012$ EuropeGermany1 $1085-1995; 1997-2006$ $1,646$ $650$ $792$ $241$ $281$ $409$ $51.1$ EuropeRomania1 $2012-2015$ $1700$ $811$ $47.65$ $633$ $37.06$ $18$ $10.59$ EuropeRomania1 $2012-2015$ $1700$ $2012$ $2014$ $2012$ $2012$ $2012$ $2012$ EuropeHolland1 $2012-2015$ $1700$ $819$ $650$ $722$ $241$ $8105$ $723$ $8105$ $12.2$ EuropeUnited Kingdom $300$ $205-2014$ $3,903$ $2466$ $650$ $722$ $203$ $8105$ $12.2$ EuropeUnited Kingdom $300$ $205-2014$ $3,903$ $844$ $904$ $70$ $723$ $8105$ $12.2$ EuropeUnited Kingdom $300$ $205-2014$ $3,903$ $842$ $70$ $726$ $8105$ $720$ EuropeUnited Kingdom $300$ $1000$ $1000$ $1000$ $1000$ <td>14</td> <td></td> <td>Australia</td> <td>1</td> <td>2005-2016</td> <td>146</td> <td>79</td> <td>54.1</td> <td>26</td> <td>17.8</td> <td>53</td> <td>36.3</td> <td>Gowda et al. 2017</td> | 14  |               | Australia      | 1                      | 2005-2016          | 146                             | 79                  | 54.1                    | 26        | 17.8             | 53    | 36.3        | Gowda et al. 2017                   |
| Europe     Switzerland     20     2008–2014     1,823     535     30.0     30.0     17.0     235     13.0       Europe     Switzerland     1     2014–2017     404     78     19.3     68     16.8     10.0     2.55       Europe     Poland     nd     2012–2015     329     150     45.6     53     16.1     97     29.5       Europe     Romania     1     1985–1995; 1997–2006     1,646     650     79.2     241     28.1     409     51.1       Europe     Romania     1     2016–2017     170     81     47.65     63     37.06     18     10.59       Europe     Holland     1     2016–2017     170     81     47.65     63     37.06     18     10.59       Europe     Holland     1     2016–2017     2014     39,3     24,4     17     28,1     409     51.1       Europe     United Kingdon     30     2012     241     24     24   | 15  |               | Turkey         | 1                      | 2010               | 925                             | 542                 | 58.6                    | 46        | 5.0              | 496   | 53.6        | Mutlu et al. 2019                   |
| EuropeSwitzerland12014-20174047819.36816.810.8102.5EuropePolandnd2012-20153291504565316.19729.5EuropeGermany11985-1995, 1997-20061,64665079.224128.140951.1EuropeGermany12016-20171708147.656337.061810.59EuropeHolland12016-2014938490.47075.314415.1EuropeHolland12016-201439.02012812.200.02337.06EuropeFrance12011-20122011 <th< td=""><td>16</td><td></td><td>Switzerland</td><td>20</td><td>2008-2014</td><td>1,823</td><td>535</td><td>30.0</td><td>300</td><td>17.0</td><td>235</td><td>13.0</td><td>Buetti et al. 2017</td></th<>   | 16  |               | Switzerland    | 20                     | 2008-2014          | 1,823                           | 535                 | 30.0                    | 300       | 17.0             | 235   | 13.0        | Buetti et al. 2017                  |
| EuropePolandnd $2012-2015$ $329$ $150$ $45.6$ $53$ $16.1$ $97$ $29.5$ EuropeGernany $1$ $1985-1995; 1997-2006$ $1,646$ $650$ $79.2$ $241$ $28.1$ $409$ $51.1$ EuropeRomania $1$ $2016-2017$ $170$ $81$ $47.65$ $63$ $37.06$ $18$ $10.59$ EuropeHolland $1$ $2016-2017$ $170$ $81$ $47.65$ $63$ $37.06$ $18$ $10.59$ EuropeHolland $1$ $2016-2017$ $201$ $201$ $204$ $70$ $75.3$ $14$ $15.1$ EuropeHolland $1$ $2011-2012$ $2011$ $393$ $2466$ $65.0$ $233$ $8.0$ $2.33$ $57.0$ EuropeGreece $16$ $2011-2012$ $2012-2015$ $3.903$ $2.466$ $65.0$ $233$ $8.0$ $2.33$ $57.0$ EuropeGreece $16$ $2012-2015$ $8.196$ $4.254$ $51.9$ $70$ $8.8$ $3.533$ $43.1$ North AmericaUSA $1$ $2002-2012$ $8.196$ $4.254$ $51.9$ $70$ $8.8$ $3.533$ $43.1$ North AmericaUSA $1$ $2002-2012$ $8.196$ $4.254$ $51.9$ $70$ $8.8$ $3.533$ $43.1$ North AmericaUSA $1$ $2002-2012$ $8.196$ $4.254$ $51.9$ $70$ $8.8$ $3.533$ $43.1$ North AmericaUSA $1$ $2012-201$   | 17  | Europe        | Switzerland    | 1                      | 2014-2017          | 404                             | 78                  | 19.3                    | 68        | 16.8             | 10    | 2.5         | Papadimitriou-Olivgeris et al. 2019 |
| EuropeGermany11985-1995; 1997-20061,64665079.224.128.140951.1EuropeRomania12016-20171708147.656337.061810.59EuropeHolland12008-2014938490.47075.314415.1EuropeHolland12008-2014938490.47075.314415.1EuropeHolland12011-20122011201120112011201220138490.4707314415.1EuropeFrance12011-201220143,9032,46665.02338.02,23357.0EuropeGreece162012-20158,1964,25451.97218.83.00Orth AmericaUSA12002-20128,1964,25451.97218.83.00North AmericaUSA12002-20128,1961,4002901112033.431North AmericaUSA12012-20138,1961,500290111522.0334341North AmericaUSA12013-201792399290111203343341North AmericaUSA1221111522.0335343North AmericaUSA12292112North A  | 18  |               | Poland         | pu                     | 2012-2015          | 329                             | 150                 | 45.6                    | 53        | 16.1             | 97    | 29.5        | Deptuła et al. 2018                 |
| Europe     Romania     1     2016-2017     170     81     47.65     63     37.06     18     10.59       Europe     Holland     1     2008-2014     93     84     90.4     70     75.3     14     15.1       Europe     Holland     1     2011-2012     2011     203     24.66     65.0     233     8.0     2.233     57.0       Europe     United Kingdom     30     2005-2014     3.903     2.466     65.0     2.33     8.0     2.233     57.0       Europe     Greece     16     2011-2012     3.903     2.466     65.0     2.33     8.0     2.233     57.0       Europe     Greece     16     2012-2012     8.196     4.554     51.9     721     8.8     30.0       North America     USA     1     2002-2012     8.196     4.554     51.9     721     8.8     3.533     43.1       North America     USA     1     2005     2012     329     4.24 <td>19</td> <td></td> <td>Germany</td> <td>1</td> <td>1997</td> <td>1,646</td> <td>650</td> <td>79.2</td> <td>241</td> <td>28.1</td> <td>409</td> <td>51.1</td> <td>Hufnagel et al. 2008</td>  | 19  |               | Germany        | 1                      | 1997               | 1,646                           | 650                 | 79.2                    | 241       | 28.1             | 409   | 51.1        | Hufnagel et al. 2008                |
| Europe     Holland     1     2008–2014     93     84     90.4     70     75.3     14     15.1       Europe     France     1     2011–2012     201     28     12.2     0     0.0     28     12.2       Europe     United Kingdom     30     205–2014     3,903     2,466     65.0     233     8.0     2,233     57.0       Europe     United Kingdom     30     205–2014     3,903     2,466     65.0     233     8.0     2,233     57.0       Europe     Greece     16     2012–2015     459     140     30.4     2     0,4     138     30.0       North America     USA     1     2006–2017     92     43.4     51.9     721     8.8     3,533     43.1       North America     USA     1     2006–2017     92     399     42.4     7     7.6     32     34.8       North America     USA     1     2006     1,500     29.0     1,115     2   | 20  | Europe        | Romania        | 1                      | 2016-2017          | 170                             | 81                  | 47.65                   | 63        | 37.06            | 18    | 10.59       | Zlatian et al. 2018                 |
| Europe     France     1     2011-2012     201     28     12.2     0     0.0     28     12.2       Europe     United Kingdom     30     205-2014     3,903     2,466     65.0     233     8.0     2,233     57.0       Europe     Greece     16     2012-2015     459     140     30.4     2     0.4     138     30.0       North America     USA     1     2002-2012     8,196     4,254     51.9     721     8.8     3,533     43.1       North America     USA     1     2006-2017     92     399     42.4     7     7     7.6     35.3     34.1       North America     USA     10     2015-2018     92.0     1500     29.0     1,115     22.0     35.5     7.0       North America     USA     1     2015-2018     5,066     1,500     29.0     1,115     22.0     35.5     7.0       North America     USA     1     24.4     7     7     <   | 21  | Europe        | Holland        | 1                      | 2008-2014          | 93                              | 84                  | 90.4                    | 70        | 75.3             | 14    | 15.1        | Zonnenberg et al. 2019              |
| Europe     United Kingdom     30     2,466     65.0     233     8.0     2,233     57.0       Europe     Greece     16     2012-2015     459     140     30.4     2     0.4     138     30.0       North America     USA     1     2002-2012     8,196     4,254     51.9     721     8.8     3,533     43.1       North America     USA     1     2002-2012     8,196     4,254     51.9     721     8.8     3,533     43.1       North America     USA     1     2002-2012     8,196     1,500     29.0     1,115     22.0     355     7.0       North America     USA     10     2015-2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2013-2017     97     29     29.0     17     17.5     22.0     355     7.0       North America     USA     1     201     29.0     19.0     17     17.5<  | 22  |               | France         | 1                      | 2011-2012          | 201                             | 28                  | 12.2                    | 0         | 0.0              | 28    | 12.2        | Butin et al. 2017                   |
| Europe     Greece     16     2012–2015     459     140     30.4     2     0.4     138     30.0       North America     USA     1     2002–2012     8,196     4,254     51.9     721     8.8     3,533     43.1       North America     USA     1     2002–2012     8,196     4,254     51.9     7.1     8.8     3,533     43.1       North America     USA     1     2006–2017     92     39     42.4     7     7.6     32     34.8       North America     USA     10     2015–2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2013–2017     97     29.0     1,715     17.5     12.4       North America     Brazil     USA     1     2012     29.1     17.4     17.5     12.4     12.4       North America     Brazil     28     20.0     29.9     17     17.5     12.4     12.4     12.4 <td>23</td> <td></td> <td>United Kingdom</td> <td></td> <td>2005-2014</td> <td>3,903</td> <td>2,466</td> <td>65.0</td> <td>233</td> <td>8.0</td> <td>2,233</td> <td>57.0</td> <td>Cailes et al. 2017</td>   | 23  |               | United Kingdom |                        | 2005-2014          | 3,903                           | 2,466               | 65.0                    | 233       | 8.0              | 2,233 | 57.0        | Cailes et al. 2017                  |
| North America     USA     1     2002-2012     8,196     4,254     51.9     721     8.8     3,533     43.1       North America     USA     1     2006-2017     92     39     42.4     7     7.6     32     34.8       North America     USA     10     2015-2018     92     39     42.4     7     7.6     32     34.8       North America     USA     10     2015-2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2013-2018     97     29     29.9     17     17.5     12.4     12.4       North America     Brazil     28     2016     47     17     36.2     6     12.8     11     23.4       South America     Brazil     32     201-2013     3,066     1,625     53.0     267     8.7     13.58     44.3   | 24  |               | Greece         | 16                     | 2012-2015          | 459                             | 140                 | 30.4                    | 2         | 0.4              | 138   | 30.0        | Gkentzi et al. 2019                 |
| North America     USA     1     2006-2017     92     39     42.4     7     7.6     32     34.8       North America     USA     10     2015-2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2015-2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2013-2017     97     29     29.9     17     17.5     12.4       South America     Brazil     28     2016     47     17     36.2     6     13.8     11.     23.4       South America     32     2001-2013     3,066     1,625     53.0     267     8.7     1,358     44.3   | 25  | North America | USA            | 1                      | 2002-2012          | 8,196                           | 4,254               | 51.9                    | 721       | 8.8              | 3,533 | 43.1        | Larru et al. 2016                   |
| North America     USA     10     2015-2018     5,066     1,500     29.0     1,115     22.0     355     7.0       North America     USA     1     2013-2017     97     29     29.9     17     17.5     12     12.4       South America     Brazil     28     2016     47     17     36.2     6     12.8     11     23.4       South America     Brazil     28     2016     47     17     36.2     6     12.8     11     23.4       South America     32     2001-2013     3,066     1,625     53.0     267     8.7     1,358     44.3   | 26  |               | USA            | 1                      | 2006-2017          | 92                              | 39                  | 42.4                    | 7         | 7.6              | 32    | 34.8        | Wagstaff et al. 2019                |
| North America     USA     1     2013–2017     97     29     29.9     17     17.5     12     12.4       South America     Brazil     28     2016     47     17     36.2     6     12.8     11     23.4       South America     Brazil     28     201-2013     3.066     1,625     53.0     267     8.7     1,358     44.3   | 27  |               | USA            | 10                     | 2015-2018          | 5,066                           | 1,500               | 29.0                    | 1,115     | 22.0             | 355   | 7.0         | Khare et al. 2019                   |
| South America     Brazil     28     2016     47     17     36.2     6     12.8     11     23.4       South America     32     2001–2013     3,066     1,625     53.0     267     8.7     1,358     44.3  | 28  |               |                | 1                      | 2013-2017          | 67                              | 29                  | 29.9                    | 17        | 17.5             | 12    | 12.4        |                                     |
| South America     22     2001–2013     3,066     1,625     53.0     267     8.7     1,358     44.3   | 29  | South America | Brazil         | 28                     | 2016               | 47                              | 17                  | 36.2                    | 9         | 12.8             | 11    | 23.4        | Braga et al. 2018                   |
|  | 30  |               | Latin America  | 32                     | 2001-2013          | 3,066                           | 1,625               | 53.0                    | 267       | 8.7              | 1,358 | 44.3        | Escalante et al. 2018               |

Worldwide staphylococcal bloodstream infections

nd – no data

group of pathogens. They concluded that the highest mortality rates were exhibited by hospital-acquired BSI (HA-BSI) pathogens, followed by community-onset healthcare-associated BSI (CHA-BSI), and the most dangerous species were CoNS and Klebsiella pneumoniae. The study from South Korea showed that CoNS were the most frequent pathogens engaged in neonatal sepsis (Lee et al. 2015). Studies in India proved a high staphylococci frequency in BSI episodes, however, gram-negative rods were mostly isolated in majority from blood samples (Bandyopadhyay et al. 2018). On the other hand, CoNS became the major isolated pathogen in neonatal sepsis in China, Nepal, Taiwan, Turkey and the Arab States, which proves widespread staphylococcal-caused sepsis in Asia (Jiang et al. 2016; Chen et al. 2017; Hammoud et al. 2017; Thapa and Sapkota 2019; Mutlu et al. 2020). These findings strongly correlate with European data.

North America and South America. In the USA research performed by Larru et al. (2016) presented similar results as European or Asian studies. The most commonly isolated pathogens were CoNS and *S. aureus*, and these pathogens were associated with healthcare-acquired BSI. Moreover, the authors confirmed that all the CoNS were evidenced as pathogens and not as contaminants. Another study from the USA showed a significant majority of *S. aureus* strains involved in neonate sepsis (Khare et al. 2020). The predisposed patients' characteristics were also comparable to those observed in Europe. These studies showed that the most endangered group consists of children and infants, especially with prolonged hospitalization.

Interestingly, children hospitalized since birth exhibited a significantly low prevalence of hospitalonset S. aureus bacteremia (Burke et al. 2009). For comparison with the USA, Latin American countries were also analyzed for staphylococcal bloodstream infections. Arias et al. (2017) presented a paper summarizing the results for nine South American countries, from Mexico to Argentina. This study did not evaluate the number of coagulase-negative staphylococci but showed many MRSA strains found in BSI samples from these countries. Notably, the highest number of participants with MRSA-associated BSI was reported in Brazil. Other studies confirmed that the prevalence of intensive-care unit-acquired infections was higher in Brazilian hospitals than in European countries and in the USA (Braga et al. 2018). On the other hand, the highest rates of CoNS (44.3%) were present in NEOCOSUR studies on five Latin American countries: Argentina, Chile, Paraguay, Peru and Uruguay (Escalante et al. 2018).

Africa. The World Health Organization (WHO) reported that, to date, information regarding blood-stream infections in Africa is scarce due to the lack of

research (Bagheri Nejad et al. 2011). However, it was estimated that the incidence of bloodstream infections (up to 14.8%) in developing countries in Africa was up to twice as high as the average European prevalence (7.1%) (ECDC 2008). The studies cited were not correlated with each other with respect to the microbiological data; the major BSI-associated pathogens presented, such as Pseudomonas aeruginosa, E. coli, K. pneumoniae, Enterobacter spp., and S. aureus, varied among papers (Bagheri Nejad et al. 2011). Besides, the most recent investigations showed a significant increase in CoNS prevalence in BSI episodes in Africa. Labi et al. (2016) showed a high number of positive blood culture samples (21.9%) among neonates, and the significant pathogens were CoNS. Nanoukon et al. (2017) obtained similar results in Benin, where S. haemolyticus and S. epidermidis were identified as the most frequently isolated pathogens. Similar results were also obtained in Egypt and Malawi (Mashaly and El-Mahdy 2017; Musicha et al. 2017). CoNS were confirmed as a major pathogen isolated in further investigations on smaller groups of patients, mostly neonates in Egypt and Ethiopia (Seliem and Sultan 2018; Sorsa et al. 2019). In contrast, a study from Zambia reports that the most frequent pathogen isolated from neonates with sepsis was Klebsiella sp. (Kabwe et al. 2016).

**Australia.** The rate of healthcare-associated BSIs in Australia is lower than reported elsewhere in the world, which was confirmed by a study in Queensland on 23 public hospitals and by research conducted by the Victorian Healthcare Associated Infection Surveillance System (VICNISS) Coordinating Centre in Victoria (Si et al. 2016; Gowda et al. 2017; Worth et al. 2018). Papers showed that the most frequently reported pathogens responsible for BSI episodes were CoNS, from 18.4 to 24.2%, and *S. aureus*, from 15.2 to 16.1%.

The distribution of all of the aforementioned staphylococcal bloodstream infections is presented in Table I.

# *S. aureus* is one of the most frequent bloodstream infection agents

According to the ECDC report, *S. aureus* is one of the major agents causing bloodstream infections in Europe. Based on the studies conducted in 25 European countries, the ECDC estimated the dynamic changes in *S. aureus* clones associated with BSI episodes. The report states that the *S. aureus* BSI infection mortality rate was 19.4% of the episodes' total number. Moreover, as expected, the MRSA all-cause mortality (24.4%) was higher than that of MSSA infections (17.1%).

Spa types related to S. aureus from BSI in Europe. ECDC also estimated 20 of the most frequent MRSA and MSSA spa types. The first group included the 5 most frequent spa types, namely, t032 (ST22, 17.9%), t003 (ST225, 8.8%), t008 (ST8, 8.4%), t002 (ST5, 7.7%), and t067 (ST125, 4.4%). Interestingly, the significant increase in incidence was related to the multilocus variable number of tandem repeats analysis type (MLVA type) ST22, and this lineage constituted 36% of the top-ranking isolates in 2011. This MRSA clone was first identified in England and was further detected in Ireland, Germany, Hungary, Portugal, and Northern Italy. The fifth most abundant spa type t067 was firstly described in Spain (Grundmann et al. 2014). In comparison, the rates of MSSA spa-type frequency were lower than those of MRSA isolates, and the 7 most popular types were t091 (ST7, 5.3%), t084 (ST15, 4.7%), t002 (ST5, 4.6%), t015 (ST45, 3.7%), t008 (ST8, 3.7%), t012 (ST30, 3.4%), and t0127 (ST1, 3.2%) (Grundmann et al. 2014). Two spa types (t008 and t002) were present in both MRSA and MSSA infections, which was probably a result of the high overall global frequency of these types, according to Ridom SpaServer (www. spaserver.ridom.de).

*Spa* types related to *S. aureus* from BSI in Poland. *S. aureus*, a key pathogen in BSI episodes, was also identified in a study conducted by our group (Ilczyszyn et al. 2016). This study, performed on neonates and children in Poland, showed the most frequent MRSA genotype to be *spa* type t003-CC5, which is consistent with the data presented by ECDC. Among MSSA strains, the most frequent genotypes belonged to the following *spa* types: t091-CC7, t037-CC30, t008-CC8, and t240-CC10. Additionally, some of the observed genotypes exhibited age-related patterns, and the *spa* type t003, *spa*-CC 002, and CC5 were strongly associated with invasive infections in infants and young children (Ilczyszyn et al. 2016).

*Spa* types related to *S. aureus* from BSI outside Europe. A study in China, performed for five years, examined *S. aureus* BSI samples and identified the most frequent *S. aureus* spa types and virulence factors. According to these data, the most frequent MRSA *spa* type in China was t030/t037, belonging to MLVA type ST239. These isolates also harbored SCC*mec* III cassette, which represents the hospital-acquired strains, and an *agr* system I. In comparison, the most frequent Chinese MSSA isolates presented the t318 type ST188 and also harbored *agr* I (Liu et al. 2018).

Latin American research divided the most numerous MRSA strains into three clades (A, B, and C) based on phylogenetic reconstruction. Strains in clade A belonged to ST5, ST105, and ST1011, and a majority of these strains harbored the gene cassette SCC*mec* I or II (HA-MRSA). Clade B consisted of the MLS types ST8, ST88, ST97, and ST72, accompanied by SCC*mec* IV variants. The last clade included Argentinian strains belonging to ST30 (Arias et al. 2017).

# Non-S. aureus staphylococci as bloodstream infection agents

Human skin is colonized by various staphylococcal species, although the most invasive is S. aureus, followed by Staphylococcus auricularis, S. capitis, S. epidermidis, S. haemolyticus, Staphylococcus hominis, S. saprophyticus, Staphylococcus simulans and Staphylococcus warneri (Yu et al. 2017). The CoNS are among the most commonly isolated microorganisms from blood samples. Compared to S. aureus strains, which are classified as invasive pathogens, the clinical significance of CoNS needs to be proven. It is essential to estimate whether the presence of CoNS represents true bacteremia or sample contamination. Many of the studies conducted have not estimated the real impact of CoNS associated with blood infections, mainly because these species are less frequent overall; have not identified these bacteria at the species level; or have not distinguished the species' differences. However, several studies have shown that CoNS can cause serious bloodstream infections (Grzebyk et al. 2013; Li et al. 2016; Szczuka et al. 2016). Therefore, host-specific capabilities and strain-specific features need to be reconsidered for an improved understanding of the course of every particular infection, as under favorable conditions, CoNS species may become highly pathogenic (Becker et al. 2014).

CoNS as BSI agents in Europe. A study performed in Belgium showed that most isolated bloodstream infection-associated CoNS strains belonged to S. epidermidis, and 77% of these strains were identified as methicillin-resistant S. epidermidis (MRSE). All of these strains presented resistance to a wide range of antibiotics, especially erythromycin (ermA, ermC, and msrA), aminoglycosides (aacA-aphD and aadC), tetracycline (tetK), and mupirocin (mupA). Molecular typing of these strains assigned 85% of the MRSE strains to clonal complex (CC) 2, consisting of the ST2, ST5, ST59, and ST88 MLVA types (Deplano et al. 2016). Another study on S. warneri strains from Poland showed their wide range of pathogenicity factors. These strains were able to adhere to host cells, produce biofilms, invade and destroy epithelial cells, which strongly facilitated bacterial persistence (Szczuka et al. 2016). This finding warrants reconsideration of the role of CoNS in bloodstream infections.

**CoNS as BSI agents in the USA.** In studies conducted in the USA, many CoNS isolates (n = 602) were found in blood samples from years 2013–2014. The most frequently isolated strains belonged to *S. epidermidis*, *S. lugdunensis*, *S. hominis*, and *S. capitis* (Sader et al. 2016). A high number of blood samples was also analyzed in Japan by Yamada et al. (2017), and 314 methicillin-resistant CoNS (MRCoNS) strains were found. Among the Japanese strains, the predominant strains

belonged to *S. epidermidis* (78.6%), *S. haemolyticus* (14.3%), and *S. capitis* subsp. *ureolyticus*. A high number of CoNS-associated BSI episodes and increasing resistance rate should also be confirmation of the danger based on the presence and spread of these bacteria.

# Conclusions

Staphylococci are among the most frequent pathogens causing bloodstream infections, which can advance to sepsis and are often observed in patients with indwelling medical devices or neonates. A high number of *S. aureus* and CoNS-related BSI episodes in high-risk patients had evidenced a significant challenge for clinicians. Many institutions widely document BSI episodes, and there has not been a worldwide decrease in these episodes. It is vital to improve existing prevention and control programs based on analysis of the data to implement standard diagnostic methods and conduct research on etiological factors, including via the usage of advanced genetic methods.

#### ORCID

Klaudia Lisowska-Łysiak https://orcid.org/0000-0001-8659-9947 Ryszard Lauterbach https://orcid.org/0000-0003-1431-6252 Jacek Międzobrodzki https://orcid.org/0000-0003-4252-880X Maja Kosecka-Strojek https://orcid.org/0000-0001-8337-6975

#### Authors' contributions

JM and MKS brought the idea of the project. KL-Ł and MKS performed the literature research and data analysis. KL-Ł, JM and MKS drafted the work. RL provided clinical consultation of the data. All authors critically revised the work.

#### Acknowledgments

This project was financed by funds No N19/MNS/000016 (to MKS) of the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University.

#### Conflict of interest

The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

#### Literature

Argemi X, Hansmann Y, Prola K, Prévost G. Coagulase-negative staphylococci pathogenomics. Int J Mol Sci. 2019 Mar 11;20(5):1215. https://doi.org/10.3390/ijms20051215

Argemi X, Hansmann Y, Riegel P, Prévost G. Is *Staphylococcus lugdunensis* significant in clinical samples? J Clin Microbiol. 2017 Nov;55(11):3167–3174. https://doi.org/10.1128/JCM.00846-17

Arias CA, Reyes J, Carvajal LP, Rincon S, Diaz L, Panesso D, Ibarra G, Rios R, Munita JM, Salles MJ, et al. A prospective cohort multicenter study of molecular epidemiology and phylogenomics of *Staphylococcus aureus* bacteremia in nine Latin American countries. Antimicrob Agents Chemother. 2017 Oct;61(10):e00816–17. https://doi.org/10.1128/AAC.00816-17 Arya R, Princy SA. An insight into pleiotropic regulators Agr and Sar: molecular probes paving the new way for antivirulent therapy. Future Microbiol. 2013 Oct;8(10):1339–1353. https://doi.org/10.2217/fmb.13.92

Ayau P, Bardossy AC, Sanchez G, Ortiz R, Moreno D, Hartman P, Rizvi K, Prentiss TC, Perri MB, Mahan M, et al. Risk Factors for 30-day mortality in patients with methicillin-resistant *Staphylococcus aureus* bloodstream infections. Int J Infect Dis. 2017 Aug;61:3–6. https://doi.org/10.1016/j.ijid.2017.05.010

**Bandyopadhyay T, Kumar A, Saili A, Randhawa VS.** Distribution, antimicrobial resistance and predictors of mortality in neonatal sepsis. J Neonatal Perinatal Med. 2018 Jul 05;11(2):145–153.

### https://doi.org/10.3233/NPM-1765

**Becker K, Heilmann C, Peters G.** Coagulase-negative staphylococci. Clin Microbiol Rev. 2014 Oct;27(4):870–926.

https://doi.org/10.1128/CMR.00109-13

Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton A, Velazquez-Acosta C, Vilar-Compte D. Bloodstream infection caused by *S. aureus* in patients with cancer: a 10-year longitudinal single-center study. Support Care Cancer. 2018 Dec;26(12):4057–4065.

https://doi.org/10.1007/s00520-018-4275-1

Bhattacharya M, Berends ETM, Chan R, Schwab E, Roy S, Sen CK, Torres VJ, Wozniak DJ. *Staphylococcus aureus* biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci USA. 2018 Jul 10;115(28):7416–7421. https://doi.org/10.1073/pnas.1721949115

Black CG, Tavares L, Stachel A, Ratner AJ, Randis TM. Distribution of late-onset neonatal sepsis pathogens differs in inpatient and outpatient settings. Am J Perinatol. 2019 Sep;36(11):1136–1141. https://doi.org/10.1055/s-0038-1675643

**Braga IA, Campos PA, Gontijo-Filho PP, Ribas RM.** Multi-hospital point prevalence study of healthcare-associated infections in 28 adult intensive care units in Brazil. J Hosp Infect. 2018 Jul;99(3): 318–324. https://doi.org/10.1016/j.jhin.2018.03.003

Buetti N, Atkinson A, Kottanattu L, Bielicki J, Marschall J, Kronenberg A; Swiss Centre for Antibiotic resistance (ANRESIS). Patterns and trends of pediatric bloodstream infections: a 7-year surveillance study. Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):537–544. https://doi.org/10.1007/s10096-016-2830-6

Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal *Staphylococcus aureus* bacteremia: epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol. 2009 Jul;30(7):636–644. https://doi.org/10.1086/597521

Butin M, Rasigade JP, Subtil F, Martins-Simões P, Pralong C, Freydière AM, Vandenesch F, Tigaud S, Picaud JC, Laurent F. Vancomycin treatment is a risk factor for vancomycin-nonsusceptible *Staphylococcus capitis* sepsis in preterm neonates. Clin Microbiol Infect. 2017 Nov;23(11):839–844.

### https://doi.org/10.1016/j.cmi.2017.03.022

Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, Bedford Russell A, Kennea N, Heath PT; neonIN network. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed. 2018 Nov;103(6):F547–F553.

#### https://doi.org/10.1136/archdischild-2017-313203

Chen CY, Tien FM, Sheng WH, Huang SY, Yao M, Tang JL, Tsay W, Tien HF, Hsueh PR. Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. Int J Antimicrob Agents. 2017 Mar;49(3):272–281.

https://doi.org/10.1016/j.ijantimicag.2016.11.009

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, Jansen KU, Gurtman A, Anderson AS. *Staphylococcus aureus*: the current state of disease, pathophysiology and strategies for prevention. Expert Rev Vaccines. 2016 Nov;15(11):1373–1392. https://doi.org/10.1080/14760584.2016.1179583

**Deplano A, Vandendriessche S, Nonhoff C, Dodémont M, Roisinenis O.** National surveillance of *Staphylococcus epidermidis* recovered from bloodstream infections in Belgian hospitals. J Antimicrob Chemother. 2016 Jul;71(7):1815–1819.

https://doi.org/10.1093/jac/dkw086

**Deptuła A, Trejnowska E, Dubiel G, Wanke-Rytt M, Deptuła M, Hryniewicz W.** Healthcare associated bloodstream infections in Polish hospitals: prevalence, epidemiology and microbiology – summary data from the ECDC Point Prevalence Survey of Healthcare Associated Infections 2012–2015. Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):565–570. https://doi.org/10.1007/s10096-017-3150-1

Dik JWH, Poelman R, Friedrich AW, Panday PN, Lo-Ten-Foe JR, Assen S, van Gemert-Pijnen JEWC, Niesters HGM, Hendrix R, Sinha B. An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID). Future Microbiol. 2016 Jan;11(1):93–102. https://doi.org/10.2217/fmb.15.99

**ECDC.** Annual epidemiological report on communicable diseases in Europe 2008. Stockholm (Sweden): European Centre for Disease Prevention and Control; 2008.

**ECDC.** Healthcare-associated infections acquired in intensive care units. In: ECDC. Annual epidemiological report for 2016. Stockholm (Sweden): European Centre for Disease Prevention and Control; 2018.

Ehlersson G, Hellmark B, Svartström O, Stenmark B, Söderquist B. Phenotypic characterisation of coagulase-negative staphylococci isolated from blood cultures in newborn infants, with a special focus on *Staphylococcus capitis*. Acta Paediatr. 2017 Oct;106(10): 1576–1582. https://doi.org/10.1111/apa.13950

Escalante MJ, Ceriani-Cernadas JM, D'Apremont I, Bancalari A, Webb V, Genes L, Villarroel L, Munoz E, Tapia JL; NEOCOSUR Neonatal Network. Late onset sepsis in very low birth weight infants in the South American NEOCOSUR Network. Pediatr Infect Dis J. 2018 Oct;37(10):1022–1027.

#### https://doi.org/10.1097/INF.000000000001958

**Foster AP.** Staphylococcal skin disease in livestock. Vet Dermatol. 2012 Aug;23(4):342–e63, e63.

https://doi.org/10.1111/j.1365-3164.2012.01093.x

Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, et al.; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant *Staphylococcus aureus* bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013 Nov;19(11):1049–1057. https://doi.org/10.1111/1469-0691.12108

Gkentzi D, Kortsalioudaki C, Cailes BC, Zaoutis T, Kopsidas J, Tsolia M, Spyridis N, Siahanidou S, Sarafidis K, Heath PT, et al.; Neonatal Infection Surveillance Network in Greece. Epidemiology of infections and antimicrobial use in Greek Neonatal Units. Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F293–F297.

https://doi.org/10.1136/archdischild-2018-315024

**Gowda H, Norton R, White A, Kandasamy Y.** Late-onset neonatal sepsis – A 10-year review from North Queensland, Australia. Pediatr Infect Dis J. 2017 Sep;36(9):883–888.

#### https://doi.org/10.1097/INF.00000000001568

Grundmann H, Schouls LM, Aanensen DM, Pluister GN, Tami A, Chlebowicz M, Glasner C, Sabat AJ, Weist K, Heuer O, et al.; ESCMID Study Group on Molecular Epidemiological Markers; European Staphylococcal Reference Laboratory Working Group. The dynamic changes of dominant clones of *Staphylococcus aureus* causing bloodstream infections in the European region: results of a second structured survey. Euro Surveill. 2014 Dec 11;19(49):20987. https://doi.org/10.2807/1560-7917.ES2014.19.49.20987 **Grzebyk M, Brzychczy-Włoch M, Piotrowska A, Krzyściak P, Heczko PB, Bulanda M.** [Phenotypic evaluation of hydrophobicity and the ability to produce biofilm in coagulase-negative staphylococci isolated from infected very-low-birthweight newborns] (in Polish). Med Dosw Mikrobiol. 2013;65(3):149–159.

Hammoud MS, Al-Taiar A, Al-Abdi SY, Bozaid H, Khan A, AlMuhairi LM, Rehman MU. Late-onset neonatal sepsis in Arab states in the Gulf region: two-year prospective study. Int J Infect Dis. 2017 Feb;55:125–130.

https://doi.org/10.1016/j.ijid.2017.01.006

Heilmann C, Ziebuhr W, Becker K. Are coagulase-negative staphylococci virulent? Clin Microbiol Infect. 2019 Sep;25(9):1071–1080. https://doi.org/10.1016/j.cmi.2018.11.012

Herrera A, Vu BG, Stach CS, Merriman JA, Horswill AR, Salgado-Pabón W, Schlievert PM. *Staphylococcus aureus* β-toxin mutants are defective in biofilm ligase and sphingomyelinase activity, and causation of infective endocarditis and sepsis. Biochemistry. 2016 May 03;55(17):2510–2517. https://doi.org/10.1021/acs.biochem.6b00083 Hosseinkhani F, Tammes Buirs M, Jabalameli F, Emaneini M, van Leeuwen WB. High diversity in SCCmec elements among multidrug-resistant *Staphylococcus haemolyticus* strains originating from paediatric patients; characterization of a new composite island. J Med Microbiol. 2018 Jul 01;67(7):915–921.

#### https://doi.org/10.1099/jmm.0.000776

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016 Dec 22;2(1):16045. https://doi.org/10.1038/nrdp.2016.45

Hufnagel M, Burger A, Bartelt S, Henneke P, Berner R. Secular trends in pediatric bloodstream infections over a 20-year period at a tertiary care hospital in Germany. Eur J Pediatr. 2008 Oct;167(10): 1149–1159. https://doi.org/10.1007/s00431-007-0651-4

Ilczyszyn WM, Sabat AJ, Akkerboom V, Szkarlat A, Klepacka J, Sowa-Sierant I, Wasik B, Kosecka-Strojek M, Buda A, Miedzobrodzki J, et al. Clonal structure and characterization of *Staphylococcus aureus* strains from invasive infections in paediatric patients from South Poland: association between age, spa types, clonal complexes, and genetic markers. PLoS One. 2016 Mar 18;11(3):e0151937. https://doi.org/10.1371/journal.pone.0151937

Ittleman BR, Szabo JS. *Staphylococcus lugdunensis* sepsis and endocarditis in a newborn following lotus birth. Cardiol Young. 2018 Nov; 28(11):1367–1369. https://doi.org/10.1017/S1047951118001300

Jiang Y, Kuang L, Wang H, Li L, Zhou W, Li M. The clinical characteristics of neonatal sepsis infection in Southwest China. Intern Med. 2016;55(6):597–603.

https://doi.org/10.2169/internalmedicine.55.3930

Kabwe M, Tembo J, Chilukutu L, Chilufya M, Ngulube F, Lukwesa C, Kapasa M, Enne V, Wexner H, Mwananyanda L, et al. Etiology, antibiotic resistance and risk factors for neonatal sepsis in a large referral center in Zambia. Pediatr Infect Dis J. 2016 Jul; 35(7):e191–e198. https://doi.org/10.1097/INF.0000000000001154

Kalińska M, Kantyka T, Greenbaum DC, Larsen KS, Władyka B, Jabaiah A, Bogyo M, Daugherty PS, Wysocka M, Jaros M, et al. Substrate specificity of *Staphylococcus aureus* cysteine proteases – Staphopains A, B and C. Biochimie. 2012 Feb;94(2):318–327. https://doi.org/10.1016/j.biochi.2011.07.020

Khare R, Kothari T, Castagnaro J, Hemmings B, Tso M, Juretschko S. Active monitoring and feedback to improve blood culture fill volumes and positivity across a large integrated health system. Clin Infect Dis. 2020 Jan 2;70(2):262–268. https://doi.org/10.1093/cid/ciz198

Kosecka-Strojek M, Buda A, Międzobrodzki J. Staphylococcal ecology and epidemiology. In: Savini V, editor. Pet-to-man travelling staphylococci. A world in progress. Cambridge (USA): Academic Press; 2018. p. 11–24.

https://doi.org/10.1016/B978-0-12-813547-1.00002-9

Kosecka-Strojek M, Ilczyszyn WM, Buda A, Polakowska K, Murzyn K, Panz T, Bialecka A, Kasprowicz A, Jakubczak A, Krol J, et al. Multiple-locus variable-number tandem repeat fingerprinting as a method for rapid and cost-effective typing of animalassociated *Staphylococcus aureus* strains from lineages other than sequence type 398. J Med Microbiol. 2016 Dec 16;65(12):1494–1504. https://doi.org/10.1099/jmm.0.000378

Kosecka-Strojek M, Sabat AJ, Akkerboom V, Becker K, van Zanten E, Wisselink G, Miedzobrodzki J, Kooistra-Smid AMDM, Friedrich AW. Development and validation of a reference data set for assigning *Staphylococcus* species based on next-generation sequencing of the 16S-23S rRNA region. Front Cell Infect Microbiol. 2019 Aug 7;9:278.

https://doi.org/10.3389/fcimb.2019.00278

Kosecka-Strojek M, Sadowy E, Gawryszewska I, Klepacka J, Tomasik T, Michalik M, Hryniewicz W, Miedzobrodzki J. Emergence of linezolid-resistant *Staphylococcus epidermidis* in the tertiary children's hospital in Cracow, Poland. Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1717–1725.

# https://doi.org/10.1007/s10096-020-03893-w

Labi AK, Obeng-Nkrumah N, Bjerrum S, Enweronu-Laryea C, Newman MJ. Neonatal bloodstream infections in a Ghanaian Tertiary Hospital: are the current antibiotic recommendations adequate? BMC Infect Dis. 2016 Dec;16(1):598.

# https://doi.org/10.1186/s12879-016-1913-4

Larru B, Gong W, Vendetti N, Sullivan KV, Localio R, Zaoutis TE, Gerber JS. Bloodstream infections in hospitalized children: epidemiology and antimicrobial susceptibilities. Pediatr Infect Dis J. 2016 May;35(5):507–510. https://doi.org/10.1097/INF.000000000001057

Lauterbach R, Wilk B, Bocheńska A, Hurkała J, Radziszewska R. Nonactivated protein c in the treatment of neonatal sepsis: a retrospective analysis of outcome. Pediatr Infect Dis J. 2016 Sep;35(9): 967–971. https://doi.org/10.1097/INF.000000000001247

**Lee SM, Chang M, Kim KS.** Blood culture proven early onset sepsis and late onset sepsis in very-low-birth-weight infants in Korea. J Korean Med Sci. 2015 Oct;30(Suppl 1):S67–74.

https://doi.org/10.3346/jkms.2015.30.S1.S67

Li S, Guo Y, Zhao C, Chen H, Hu B, Chu Y, Zhang Z, Hu Y, Liu Z, Du Y, et al. *In vitro* activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospitalacquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China. J Med Microbiol. 2016 Oct 18;65(10):1215–1224.

#### https://doi.org/10.1099/jmm.0.000347

Lisowska-Łysiak K, Kosecka-Strojek M, Białecka J, Kasprowicz A, Garbacz K, Piechowicz L, Kmet V, Savini V, Międzobrodzki J. New insight into genotypic and phenotypic relatedness of *Staphylococcus aureus* strains from human infections or animal reservoirs. Pol J Microbiol. 2019;68(1):93–104.

# https://doi.org/10.21307/pjm-2019-011

Liu Y, Du F, Liu P, Mei Y, Wan L, Wei D, Xu H, Zhang W. Molecular epidemiology and virulence features of *Staphylococcus aureus* bloodstream isolates in a regional burn center in China, 2012–2016. Microb Drug Resist. 2018 Nov;24(9):1354–1360.

#### https://doi.org/10.1089/mdr.2017.0209

Martínez-García S, Rodríguez-Martínez S, Cancino-Diaz ME, Cancino-Diaz JC. Extracellular proteases of *Staphylococcus epidermidis*: roles as virulence factors and their participation in biofilm. APMIS. 2018 Mar;126(3):177–185.

### https://doi.org/10.1111/apm.12805

Mashaly GES, El-Mahdy RH. Vancomycin heteroresistance in coagulase negative *Staphylococcus* blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt. Ann Clin Microbiol Antimicrob. 2017 Dec;16(1):63. https://doi.org/10.1186/s12941-017-0238-5

Michalik S, Sundaramoorthy N, Murr A, Depke M, Völker U, Bröker BM, Aamot HV, Schmidt F. Early-stage *Staphylococcus aureus* bloodstream infection causes changes in the concentrations of lipoproteins and acute-phase proteins and is associated with low antibody titers against bacterial virulence factors. mSystems. 2020 Jan 21;5(1):e00632–19. https://doi.org/10.1128/mSystems.00632-19 Miedzobrodzki J, Kaszycki P, Bialecka A, Kasprowicz A. Proteolytic activity of *Staphylococcus aureus* strains isolated from the colonized skin of patients with acute-phase atopic dermatitis. Eur J Clin Microbiol Infect Dis. 2002 Apr;21(4):269–276.

https://doi.org/10.1007/s10096-002-0706-4

Minejima E, Delayo V, Lou M, Ny P, Nieberg P, She RC, Wong-Beringer A. Utility of qSOFA score in identifying patients at risk for poor outcome in *Staphylococcus aureus* bacteremia. BMC Infect Dis. 2019 Dec;19(1):149. https://doi.org/10.1186/s12879-019-3770-4 Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C, Denis B, Kennedy N, Mallewa J, Gordon MA, Msefula CL, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998–2016): a surveillance study. Lancet Infect Dis. 2017 Oct;17(10):1042–1052.

#### https://doi.org/10.1016/S1473-3099(17)30394-8

Mutlu M, Aslan Y, Aktürk Acar F, Kader Ş, Bayramoğlu G, Yılmaz G. Changing trend of microbiologic profile and antibiotic susceptibility of the microorganisms isolated in the neonatal nosocomial sepsis: a 14 years analysis. J Matern Fetal Neonatal Med. 2020 Nov; 33(21): 3658–3665. https://doi.org/10.1080/14767058.2019.1582633

Nanoukon C, Affolabi D, Keller D, Tollo R, Riegel P, Baba-Moussa L, Prévost G. Characterization of human type C enterotoxin produced by clinical *S. epidermidis* isolates. Toxins (Basel). 2018 Mar 27;10(4):139. https://doi.org/10.3390/toxins10040139

Nanoukon C, Argemi X, Sogbo F, Orekan J, Keller D, Affolabi D, Schramm F, Riegel P, Baba-Moussa L, Prévost G. Pathogenic features of clinically significant coagulase-negative staphylococci in hospital and community infections in Benin. Int J Med Microbiol. 2017 Jan;307(1):75–82. https://doi.org/10.1016/j.ijmm.2016.11.001 Natoli S, Fontana C, Favaro M, Bergamini A, Testore GP, Minelli S, Bossa MC, Casapulla M, Broglio G, Beltrame A, et al. Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. BMC Infect Dis. 2009 Dec;9(1):83.

#### https://doi.org/10.1186/1471-2334-9-83

Nejad SB, Allegranzi B, Syed S, Ellis B, Pittet D. Health-care-associated infection in Africa: a systematic review. Bull World Health Organ. 2011 Oct 1;89(10):757–765.

#### https://doi.org/10.2471/BLT.11.088179

**Oliveira D, Borges A, Simões M.** *Staphylococcus aureus* toxins and their molecular activity in infectious diseases. Toxins (Basel). 2018 Jun 19;10(6):252. https://doi.org/10.3390/toxins10060252

**Pai S, Enoch DA, Aliyu SH.** Bacteremia in children: epidemiology, clinical diagnosis and antibiotic treatment. Expert Rev Anti Infect Ther. 2015 Sep 02;13(9):1073–1088.

#### https://doi.org/10.1586/14787210.2015.1063418

Papadimitriou-Olivgeris M, Psychogiou R, Garessus J, Camaret AD, Fourre N, Kanagaratnam S, Jecker V, Nusbaumer C, Monnerat LB, Kocher A, et al. Predictors of mortality of bloodstream infections among internal medicine patients in a Swiss hospital: role of quick Sequential Organ Failure Assessment. Eur J Intern Med. 2019 Jul;65:86–92. https://doi.org/10.1016/j.ejim.2019.05.003 Sabat AJ, van Zanten E, Akkerboom V, Wisselink G, van Slochteren K, de Boer RF, Hendrix R, Friedrich AW, Rossen JWA, Kooistra-Smid AMD. Targeted next-generation sequencing of the 16S–23S rRNA region for culture-independent bacterial identification – increased discrimination of closely related species. Sci Rep. 2017 Dec;7(1):3434.

https://doi.org/10.1038/s41598-017-03458-6

Sabat AJ, Wladyka B, Kosowska-Shick K, Grundmann H, van Dijl J, Kowal J, Appelbaum PC, Dubin A, Hryniewicz W. Polymorphism, genetic exchange and intragenic recombination of the aureolysin gene among *Staphylococcus aureus* strains. BMC Microbiol. 2008;8(1):129. https://doi.org/10.1186/1471-2180-8-129

Sader HS, Farrell DJ, Flamm RK, Streit JM, Mendes RE, Jones RN. Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative *Staphylococcus* causing infection in US hospitals. Diagn Microbiol Infect Dis. 2016 May;85(1):80–84.

https://doi.org/10.1016/j.diagmicrobio.2016.01.010

Samet A, Bronk M, Sledzińska A, Labon M, Rybak B. [Nosocomial bacteremia] (in Polish). Przegl Epidemiol. 2006;60(1):35–41.

Seliem WA, Sultan AM. Etiology of early onset neonatal sepsis in neonatal intensive care unit – Mansoura, Egypt. J Neonatal Perinatal Med. 2018 Sep 28;11(3):323–330.

#### https://doi.org/10.3233/NPM-17128

Si D, Runnegar N, Marquess J, Rajmokan M, Playford EG. Characterising health care-associated bloodstream infections in public hospitals in Queensland, 2008–2012. Med J Aust. 2016 Apr; 204(7):276. https://doi.org/10.5694/mja15.00957

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016 Feb 23; 315(8):801–810. https://doi.org/10.1001/jama.2016.0287

**Sorsa A, Früh J, Stötter L, Abdissa S.** Blood culture result profile and antimicrobial resistance pattern: a report from neonatal intensive care unit (NICU), Asella teaching and referral hospital, Asella, south East Ethiopia. Antimicrob Resist Infect Control. 2019 Dec;8(1):42. https://doi.org/10.1186/s13756-019-0486-6

Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R, et al. Sepsis: the LightCycler SeptiFast Test MGRADE\*, SepsiTest<sup>™</sup> and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation. Health Technol Assess. 2016 Jun;20(46):1–246. https://doi.org/10.3310/hta20460 Szczuka E, Krzymińska S, Kaznowski A. Clonality, virulence and the occurrence of genes encoding antibiotic resistance among *Staphylococcus warneri* isolates from bloodstream infections. J Med Microbiol. 2016 Aug 01;65(8):828–836.

#### https://doi.org/10.1099/jmm.0.000287

Takeshita N, Kawamura I, Kurai H, Araoka H, Yoneyama A, Fujita T, Ainoda Y, Hase R, Hosokawa N, Shimanuki H, et al. Unique characteristics of community-onset healthcare-associated bloodstream infections: a multi-centre prospective surveillance study of bloodstream infections in Japan. J Hosp Infect. 2017 May; 96(1):29–34. https://doi.org/10.1016/j.jhin.2017.02.022

**Tevell S, Hellmark B, Nilsdotter-Augustinsson Å, Söderquist B.** *Staphylococcus capitis* isolated from prosthetic joint infections. Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):115–122.

# https://doi.org/10.1007/s10096-016-2777-7

**Thapa S, Sapkota LB.** Changing trend of neonatal septicemia and antibiotic susceptibility pattern of isolates in Nepal. Int J Pediatr. 2019 Feb 06;2019:1–7. https://doi.org/10.1155/2019/3784529

Thomer L, Schneewind O, Missiakas D. Pathogenesis of *Staphylococcus aureus* bloodstream infections. Annual Review of Pathology: Mechanisms of Disease. 2016 May 23;11(1):343–364. https://doi.org/10.1146/annurev-pathol-012615-044351

Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015 Jul;28(3):603–661. https://doi.org/10.1128/CMR.00134-14

Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP. Vancomycin resistance in *Staphylococcus haemolyticus* causing colonization and bloodstream infection. J Clin Microbiol. 1990;28(9):2064–2068. https://doi.org/10.1128/JCM.28.9.2064-2068.1990

von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulasenegative staphylococci. Lancet Infect Dis. 2002 Nov;2(11): 677–685. https://doi.org/10.1016/S1473-3099(02)00438-3

Wagstaff JS, Durrant RJ, Newman MG, Eason R, Ward RM, Sherwin CMT, Enioutina EY. Antibiotic treatment of suspected and confirmed neonatal sepsis within 28 days of birth: A retrospective analysis. Front Pharmacol. 2019 Oct 15;10:1191.

https://doi.org/10.3389/fphar.2019.01191

Wójkowska-Mach J, Chmielarczyk A, Strus M, Lauterbach R, Heczko P. Neonate bloodstream infections in organization for economic cooperation and development countries: an update on epidemiology and prevention. J Clin Med. 2019 Oct 21;8(10):1750. https://doi.org/10.3390/jcm8101750

Wójkowska-Mach J, Gulczyńska E, Nowiczewski M, Borszewska-Kornacka M, Domańska J, Merritt TA, Helwich E, Kordek A, Pawlik D, Gadzinowski J, et al. Late-onset bloodstream infections of very-low-birth-weight infants: data from the Polish Neonatology Surveillance Network in 2009–2011. BMC Infect Dis. 2014 Dec; 14(1):339. https://doi.org/10.1186/1471-2334-14-339

**Worth LJ, Daley AJ, Spelman T, Bull AL, Brett JA, Richards MJ.** Central and peripheral line-associated bloodstream infections in Australian neonatal and paediatric intensive care units: findings from a comprehensive Victorian surveillance network, 2008–2016. J Hosp Infect. 2018 May;99(1):55–61.

#### https://doi.org/10.1016/j.jhin.2017.11.021

Yamada K, Namikawa H, Fujimoto H, Nakaie K, Takizawa E, Okada Y, Fujita A, Kawaguchi H, Nakamura Y, Abe J, et al. Clinical characteristics of methicillin-resistant coagulase-negative staphylococcal bacteremia in a tertiary hospital. Intern Med. 2017;56(7):781–785. https://doi.org/10.2169/internalmedicine.56.7715

Yu W, Kim HK, Rauch S, Schneewind O, Missiakas D. Pathogenic conversion of coagulase-negative staphylococci. Microbes Infect. 2017 Feb;19(2):101–109.

#### https://doi.org/10.1016/j.micinf.2016.12.002

Zingg W, Hopkins S, Gayet-Ageron A, Holmes A, Sharland M, Suetens C, Almeida M, Asembergiene J, Borg MA, Budimir A, et al.; ECDC PPS study group. Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infect Dis. 2017 Apr;17(4):381–389. https://doi.org/10.1016/S1473-3099(16)30517-5

Zlatian O, Balasoiu A, Balasoiu M, Cristea O, Docea A, Mitrut R, Spandidos D, Tsatsakis A, Bancescu G, Calina D. Antimicrobial resistance in bacterial pathogens among hospitalised patients with severe invasive infections. Exp Ther Med. 2018 Sep 14;16(6):4499–4510. https://doi.org/10.3892/etm.2018.6737

Zonnenberg IA, van Dijk-Lokkart EM, van den Dungen FAM, Vermeulen RJ, van Weissenbruch MM. Neurodevelopmental outcome at 2 years of age in preterm infants with late-onset sepsis. Eur J Pediatr. 2019 May;178(5):673–680.

https://doi.org/10.1007/s00431-019-03339-2